Current treatment status-Did not start treatment yet - Page 3 of 37 Posts on Medivizor
Navigation Menu

Current treatment status-Did not start treatment yet Posts on Medivizor

Evaluating lenalidomide-rituximab treatment for follicular lymphoma

Evaluating lenalidomide-rituximab treatment for follicular lymphoma

Posted by on Aug 23, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the effectiveness of rituxumab (Rituxan) with lenalidomide (Revlimid) for untreated follicular lymphoma (FL). It found that this treatment was more effective than rituxumab with chemotherapy. They also found that blood tests of trace FL can predict outcomes. Some background Follicular lymphoma (FL) is a slow-growing...

Read More

Looking for patients with untreated extensive-stage small cell lung cancer to trial a immunotherapy combination

Looking for patients with untreated extensive-stage small cell lung cancer to trial a immunotherapy combination

Posted by on Aug 15, 2020 in Lung cancer | 0 comments

In a nutshell This trial is examining the effectiveness of atezolizumab (Tecentriq) plus carboplatin (Paraplatin) and etoposide (Etopophos) with or without tiragolumab in patients with untreated extensive-stage small-cell lung cancer (ES-SCLC). The main outcomes that will be measured are progression-free survival (PFS) and overall survival...

Read More

Treating BRAFV600 mutation-positive advanced melanoma with atezolizumab, vemurafenib, and cobimetinib

Treating BRAFV600 mutation-positive advanced melanoma with atezolizumab, vemurafenib, and cobimetinib

Posted by on Jul 12, 2020 in Melanoma | 0 comments

In a nutshell The study evaluated whether the combination of atezolizumab (Tecentriq), vemurafenib (Zelboraf), and cobimetinib (Cotellic) or AVC can effectively treat patients with BRAFV600 mutation-positive advanced melanoma (AM). The authors found that this combination was safe and effective as an initial treatment in such...

Read More

Comparing the long-term effects of two intensity modulated radiation therapies in localized prostate cancer

Comparing the long-term effects of two intensity modulated radiation therapies in localized prostate cancer

Posted by on Jun 28, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared the long-term effects of moderate hypofractionated intensity-modulated radiation therapy (H-IMRT) and conventionally fractionated IMRT (C-IMRT) on outcomes in patients with localized prostate cancer (PC). The authors found that H-IMRT was similarly effective compared to C-IMRT after 10 years of therapy in such...

Read More

Evaluating the effects of chemotherapy on cognitive function in patients with early breast cancer

Evaluating the effects of chemotherapy on cognitive function in patients with early breast cancer

Posted by on Jun 28, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated the contribution of chemotherapy on cancer-related cognitive impairment (CRCI) reported by women with early breast cancer. The authors found that chemotherapy added to hormonal therapy caused early and short-term CRCI in such patients, compared to hormonal therapy alone. Some background CRCI refers to problems in...

Read More

Higher or lower radiotherapy dose for patients with non-Hodgkin lymphoma undergoing stem cell transplantation?

Higher or lower radiotherapy dose for patients with non-Hodgkin lymphoma undergoing stem cell transplantation?

Posted by on May 26, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined how effective and safe a higher radiotherapy dose was for patients with non-Hodgkin lymphoma (NHL) undergoing stem cell transplantation (SCT). The authors found that patients who received a lower radiotherapy dose survived longer and had fewer side effects than the higher dose. Some background NHL is a cancer of...

Read More

Managing joint and muscle pain in patients with chronic lymphocytic leukemia treated with ibrutinib

Posted by on Apr 14, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the occurrence and risks of joint/muscle pain as side effects of ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL). The authors found that 36% of patients developed joint/muscle pain and most were younger and females receiving ibrutinib as the first treatment. Some background Ibrutinib kills...

Read More

Does immune cell boosting drug G-CSF reduce the effects of chemotherapy in different cancers?

Does immune cell boosting drug G-CSF reduce the effects of chemotherapy in different cancers?

Posted by on Apr 5, 2020 in Breast cancer | 0 comments

In a nutshell This study examined the effects of granulocyte colony-stimulating factor (G-CSF) given as a preventative measure in patients with high- and medium-risk cancer receiving chemotherapy. The results showed that preventative G-CSF allowed more patients to complete chemotherapy treatment and lowered patients’ chances of developing...

Read More

How useful is preimplantation genetic testing for aneuploidy for fertility preservation in cancer patients?

Posted by on Feb 22, 2020 in Leukemia | 0 comments

In a nutshell This study investigated preimplantation genetic testing for aneuploidy (PGT-A) for fertility preservation (FP).  They found that PGT-A was useful in cancer patients attempting FP.  Some background Assisted reproductive technology (ART) is used to treat infertility. It is also an important option for cancer patients. Cancer...

Read More